glp glp-1 How medications are transforming diabetes and weight loss treatment Targeting GLP-1, GIP & GCG

No difference was observed between frailty groups

Observational real-world data in patients with T2D receiving oral semaglutide for 26 weeks demonstrated preservation of fat-free and skeletal muscle mass despite significant losses in fat mass and visceral adipose tissue, suggesting that the magnitude of lean tissue change may depend on concomitant lifestyle behaviors, such as physical activity and diet [16]

Cannabinoids for control of chemotherapy induced nausea and vomiting: Quantitative systematic review

Patients who prefer the regulatory assurance of FDA-approved manufacturing, or who have insurance coverage for branded GLP-1, may prefer the branded option

Patients who respond inadequately to semaglutide alone often benefit from switching to tirzepatidea dual GLP-1 and GIP receptor agonist that activates additional appetite-suppression pathwaysrather than adding a stimulant medication

Abboud KY, Reis SK, Martelli ME, et al